DavidBajorMD

Oncology • Cleveland, OH

Gastrointestinal Cancer, Hematologic Oncology, Melanoma

Instructor

Join to view full profile

Dr. Bajor is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Bajor's full profile

Already have an account?

Office
11100 Euclid Ave
Cleveland, OH 44106
Phone+1 216-844-3951

Fax+1 216-844-5759

Education & Training

University of Pennsylvania Health SystemFellowship, Hematology and Medical Oncology, 2010 - 2013
University of Pennsylvania Health SystemResidency, Internal Medicine, 2007 - 2010
Case Western Reserve University School of MedicineClass of 2007

Certifications & Licensure

OH State Medical License 2016 - 2025
PA State Medical License 2007 - 2016
American Board of Internal Medicine Medical Oncology

Clinical Trials

CB-839 + Capecitabine in Solid Tumors and Fluoropyrimidine Resistant PIK3CA Mutant Colorectal Cancer Start of enrollment: 2016 Sep 12
COMPLETED
PHASE1, PHASE2

Publications & Presentations

PubMed

Real-World Tolerability of Capecitabine and Oxaliplatin in Patients in the United States With Localized Colorectal Cancer Undergoing Curative-Intent Treatment.
Veronica Mears, Nikolas Naleid, Omkar Pawar, Jennifer Eva Selfridge, Madison Conces
JCO Oncology Practice. 2025-03-04
CITRINO: phase 1 dose escalation study of anti-LAG-3 antibody encelimab alone or in combination with anti-PD-1 dostarlimab in patients with advanced/metastatic solid t...
J Randolph Hecht, Jean-Marie Michot, David Bajor, Amita Patnaik, Ki Y Chung
BJC Reports. 2025-02-27
Safety and Efficacy of Toripalimab in Patients with Cholangiocarcinoma: An Open-Label, Phase 1 Study.
Aung Naing, Amit Mahipal, Milind Javle, Judy Wang, Todd M Bauer
Journal of Immunotherapy and Precision Oncology. 2025-02-01

Press Mentions

Combining Two Cancer Drugs Can Be Effective in Treating Specific Type of Colorectal Cancer, Study ShowsMay 2nd, 2022
Adoptive Cell TherapyDecember 12th, 2018
Immunotherapy Combo Appears Safe, Shrinks Metastatic Melanoma TumorsJune 2nd, 2015
Join now to see all